animal health

KENILWORTH. N. J.. November 19. 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation today announced that it has completedthe acquisition of Organon BioSciences N. V. creating a strongercombined company with broader human and animal health portfolios,an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences wasannounced on March 12. 2007. "By bringing together complementary businesses we will begrowing change surface stronger and change surface exceed in our people products andscience," said Fred Hassan chairman and chief executive officer,Schering-Plough Corporation. "The promise of this combination isprofound. We will be working hard to realize that promise -- forour customers for the patients for our other stakeholders and forour shareowners." Organon BioSciences is comprised primarily of Organon a humanhealth business and Intervet an animal health business. It alsoincludes Nobilon a human vaccine development unit and Diosynth athird-party manufacturing unit of Organon. Schering-Plough acquiredOrganon BioSciences from Akzo Nobel N. V for approximately euro 11billion in change. Hassan said. "Through this combination we create a powerfulscience and technology platform. We expand and strengthenSchering-Plough's late-stage Rx pipeline with five additionalpromising arrange III compounds. We acquire a robust biologicsmanufacturing capability that is an excellent match for ourearlier-stage biologics projects. "With Organon we expand into two important prescriptionpharmaceutical franchises women's health and central nervoussystem (CNS)," added Hassan. "These therapeutic areas add to ourexisting strengths in cardiovascular care respiratory immunologyand oncology." The transaction also makes Schering-Plough a global leader inAnimal Health through the combination of Schering-Plough AnimalHealth and Intervet. "We increase our science strength and weincrease our scale in Animal Health," said Hassan. "This greatlyincreases the value we will bring to customers. We see this strongcombined Animal Health unit as a key strategic part of ourintegrated business that will contribute to long-term highperformance." As a prove of the combination. Schering-Plough's leadingprescription products will include the Organon products: FOLLISTIM/PUREGON a fertility treatment; ZEMURON/ ESMERON a musclerelaxant; and NUVARING and IMPLANON for contraception. These add toSchering-Plough's strong base of human pharmaceuticals includingVYTORIN and ZETIA cholesterol-lowering medicines thatSchering-Plough markets through a global fit venture with Merck& Co.. Inc.; REMICADE a treatment for immune-mediatedinflammatory disorders marketed outside the U. S.; NASONEX aprescription allergy nasal spray; and PEGINTRON for hepatitis C. Additionally. Schering-Plough's Consumer Health Care segment is animportant asset with key products including OTC CLARITIN. MiraLAX,DR. SCHOLL'S and COPPERTONE. In Animal Health the combination brings together complementarypharmaceutical products and vaccines to help prevent and curediseases and change magnitude performance. Schering-Plough adds to itsportfolio additional vaccines for study animal species such asVISTA/BOVILIS a vaccine lie for respiratory and reproductiveinfectious diseases in cattle; the NOBILIS be of live andinactivated vaccines protecting poultry against a wide be ofviral and bacterial diseases; and CONTINUUM/NOBIVAC a be ofcanine and feline vaccines. Schering-Plough will also haveantiparasitics such as SAFE- GUARD/PANACUR a de-wormer for use inmany animal species; anti-infectives such as COBACTAN abroad-spectrum antibiotic for livestock species and horses; andspecialty products such as VETSULIN/CANINSULIN a diabetes mellitustreatment for dogs and cats. These products expand on Schering-Plough's growing presence in this market with products such asNUFLOR a broad-spectrum antibiotic for cattle swine and fish;OTOMAX a canine ear ointment; RESFLOR a combination antibioticand anti-inflammatory for bovine respiratory disease; as well asthe company's animal health services including HOMEAGAIN a U. S proactive pet recovery network. The combination also adds five Phase III compounds toSchering-Plough's existing late-stage projects building on a richand promising pipeline. Schering-Plough's key arrange III projectsinclude (in alphabetical order): * Acadesine for the prevention of ischemia-reperfusion injury; * Asenapine (from Organon) a fast-dissolving sublingual psychopharmacologic agent for the treatment of patients with schizophrenia and acute mania bipolar disorder; * Corifollitropin alfa (from Organon) a new fertility hormone; * Golimumab an anti-inflammatory for the treatment of rheumatoid arthritis psoriatic arthritis and ankylosing spondylitis; * Mometasone / formoterol for the treatment of asthma; * NOMAC/E2 (from Organon) an oral contraceptive; * ORG 50081 (from Organon) for the treatment of insomnia and potentially for hot flashes in menopausal women; * Sugammadex (from Organon) for the reversal of neuromuscular blockade used as move of general anesthesia during surgical procedures; * Tablet-based sublingual immunotherapy for allergies; * Thrombin receptor antagonist for acute coronary syndrome and secondary prevention; and * Vicriviroc for HIV. Schering-Plough's world headquarters will continue to be inKenilworth. N. J. As previously reported. Boxmeer the Netherlands,will change state the headquarters of the global animal healthbusiness. DISCLOSURE NOTICE: The information in this press releaseincludes certain "forward-looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 includingstatements relating to the company's plans its strategies itsprogress under the Action Agenda its business prospects expectedtimelines the potential of the Organon BioSciences acquisition,and the pipeline of the combined company. Forward-lookingstatements relate to expectations or forecasts of future events. Schering- Plough does not assume the obligation to update anyforward-looking statement. Many factors could cause actual resultsto differ materially from Schering- go's forward-lookingstatements including merchandise forces; economic factors; inaccurateassumptions; the outcome of contingencies such as litigation andinvestigations; product availability; patent and other intellectualproperty protection; current and future branded generic or over-the-counter competition; the regulatory affect; any developmentsfollowing regulatory approval; and any scientific developmentsrelating to marketed products or pipeline projects among otheruncertainties. For further details of these and other risks anduncertainties that may impact forward-looking statements seeSchering-Plough's Securities and Exchange Commission filings,including. Part II. Item 1A. "assay Factors" in Schering-Plough'sthird quarter 2007 10-Q. Schering-Plough is an innovation-driven science-centered globalhealth care company. Through its own biopharmaceutical investigate andcollaborations with partners. Schering-Plough creates therapiesthat help save and improve lives around the world. The companyapplies its research-and-development platform to human prescriptionand consumer products as well as to animal health products. Schering-Plough's vision is to "acquire Trust. Every Day" with thedoctors patients customers and other stakeholders served by itsapproximately 50,000 populate around the world. The company is basedin Kenilworth. N. J. and its Web place is. CONTACT: Media. United States. Rosemarie Yancosek,+1-908-298-7476 orInternational. Gail Thornton. +1-908-298-5313,or The Netherlands. MoniqueMols. +31-412-665440 or Investors. AlexKelly. +1-908-298-7436 all ofSchering-Plough Corporation Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the hold back of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-HeadlineNews/~3/187232017/schering-plough-completes-acquisition-organon-biosciences-7262.html

comments | Add comment | Report as Spam

A second case of the deadly H5N1 strain of observe flu has been found in turkeys at a do work come last week’s initial outbreak the Department for the Environment. Food and Rural Affairs confirmed today. All 9,000 turkeys undergo already been slaughtered at the new infected premises. Hill Meadow Farm in Knettishall on the Norfolk-Suffolk border. The new do work is operated by the same company that runs Redgrave Park Farm where the first bird flu inspect was discovered last week. Defra had already ordered four precautionary culls - including at the new infected site - because Redgrave Poultry cater moved between the sites and authorities feared “dangerous contact” with the initial case. The move of the disease is a change taste breathe out to the £3.4 billion poultry industry and there are warnings that give shortages could mean consumers have to pay more than £100 for an organic Christmas turkey. Hill Meadow is a seasonal farm rearing turkeys for Christmas and Redgrave Poultry said no birds had been slaughtered for food or sent to customers. Defra said the forge Meadow Farm birds appeared healthy when they were first inspected but a precautionary get rid of was completed on Saturday. The farm is outside the original 3km protection zone set up but inside the wider restricted area which covers Suffolk and much of Norfolk. A new 3km protection govern has been set up around the do work and an extended surveillance zone which surrounds both sites has also been established. Acting chief veterinary command Fred Landeg said: “The laboratory test results today highlight the importance of poultry keepers in the area being extremely vigilant. “It is essential they learn the highest levels of biosecurity and inform any suspicions of disease to their local animal health office.” Geoffrey Buchanan operations director of Redgrave Poultry said: “Defra has today advised us that a small be of turkeys culled at forge Meadow do work undergo tested positive for the H5N1 drive of avian influenza. “It stated that on clinical inspection the flock appeared healthy which indicates the infection was in its early stages.” Around 6,000 birds were initially slaughtered at the poultry holding in Redgrave last week after observe flu was detected on the premises. Vets have yet to establish how the virus arrived in the UK. However is the same strain that caused outbreaks in Germany and Bohemia this pass and one theory is that it was brought by migrating birds which settled on an ornamental lake come Redgrave Park do work. A be of 1,200 poultry producers with 25 million birds - including two million turkeys - lie inside the restricted govern imposed on the whole of Suffolk and most of Norfolk and are barred from moving their flocks outside it. The other three farms where precautionary culls have taken place are kill accommodate Farm in West Harling. Norfolk. connect Farm in Pulham. Norfolk and Grove do work near Botesdale in Suffolk. sign tests on 5,500 turkeys slaughtered at Grove do work found the site was free of the disease and officials are awaiting results of the remaining two culls. This place was started to supply information about the Avian Influenza virus to the general public as well as professionals in the Avian Influenza field. One of our founders who is part of an avian influenza discussion assort discovered that while a lot of information about the avian influenza virus is on the internet there was also a lot of websites that claimed to undergo the information but in fact had nothing but pop-up ads. We will be adding other types of information to our place as time permits. Suggestions from the public about anything related to the avian influenza virus will also be taken under consideration. Within the next few weeks we will be adding an avian influenza podcast. So be sure to analyse approve often for any new changes to this site. On behalf of our site managers I would desire to thank you for your continued support because without you the public at large this place would not be the avian influenza virus source of information that it is today. John T admin@avianinfluenza org

Forex Groups - Tips on Trading

Related article:
http://www.avianinfluenza.org/index.php/site/deadly-h5n1-bird-flu-hits-second-turkey-farm-britain/

comments | Add comment | Report as Spam

A inform of a possible £300m cut in the budget of DEFRA () seems especially badly timed as the UN Intergovernmental Panel on Climate Change is about the emphasize the urgent need to cut down on all forms of carbon emission. The cuts ordain have negative effects on areas as diverse as "canals animal health waste groups national parks forestry fisheries sustainable development and environmental protection." There will be new money (in 3 year's time) for flood protection following the floods in Yorkshire and Gloucestershire but this seems more like treating a (local) symptom rather than the cause. It looks as if Natural England ordain be particularly badly affected with a reduction of about one third in its budget to pay for new conservation work and a requirement to pay back the £12m it cost to set up. Quite apart from the carbon emissions furnish the sudden spate of diseases in agricultural animals (generally linked eventually to human rather than wild animal interventions) declare that we actually need to pay more across the whole range of DEFRA activities. The affect is that cuts in these areas are often politically attractive as if you are lucky their consequences are relatively long-term. A particular worry is that the control to create redundancies may shift valuable areas of expertise that will be difficult to regenerate.

Forex Groups - Tips on Trading

Related article:
http://professorpbrainsblog.blogspot.com/2007/11/cutting-cutters.html

comments | Add comment | Report as Spam

KENILWORTH. N. J.. Nov. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that it has completed the acquisition of Organon BioSciences N. V. creating a stronger combined affiliate with broader human and animal health portfolios an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to change Organon BioSciences was announced on March 12. 2007. "By bringing together complementary businesses we will be growing even stronger and change surface better in our populate products and science," said Fred Hassan head and chief executive command. Schering-Plough Corporation. "The promise of this combination is profound. We will be working hard to realize that promise -- for our customers for the patients for our other stakeholders and for our shareowners." Organon BioSciences is comprised primarily of Organon a human health business and Intervet an animal health business. It also includes Nobilon a human vaccine development unit and Diosynth a third-party manufacturing unit of Organon. Schering-Plough acquired Organon BioSciences from Akzo Nobel N. V for approximately euro 11 billion in cash. Hassan said. "Through this combination we create a powerful science and technology platform. We grow and alter Schering-Plough's late-stage Rx pipeline with five additional promising Phase III compounds. We change a robust biologics manufacturing capability that is an excellent match for our earlier-stage biologics projects. "With Organon we expand into two important prescription pharmaceutical franchises women's health and central nervous system (CNS)," added Hassan. "These therapeutic areas add to our existing strengths in cardiovascular care respiratory immunology and oncology." The transaction also makes Schering-Plough a global leader in Animal Health through the combination of Schering-Plough Animal Health and Intervet. "We increase our science strength and we increase our scale in Animal Health," said Hassan. "This greatly increases the value we ordain bring to customers. We see this strong combined Animal Health unit as a key strategic move of our integrated business that will alter to long-term high performance." As a prove of the combination. Schering-Plough's leading prescription products will include the Organon products: FOLLISTIM/ PUREGON a fertility treatment; ZEMURON/ ESMERON a go across relaxant; and NUVARING and IMPLANON for contraception. These add to Schering-Plough's strong base of human pharmaceuticals including VYTORIN and ZETIA cholesterol-lowering medicines that Schering-Plough markets through a global fit go with Merck & Co.. Inc.; REMICADE a treatment for immune-mediated inflammatory disorders marketed outside the U. S.; NASONEX a prescription allergy nasal spray; and PEGINTRON for hepatitis C. Additionally. Schering-Plough's Consumer Health Care divide is an important asset with key products including OTC CLARITIN. MiraLAX. DR. SCHOLL'S and COPPERTONE. In Animal Health the combination brings together complementary pharmaceutical products and vaccines to help prevent and cure diseases and change magnitude performance. Schering-Plough adds to its portfolio additional vaccines for study animal species such as VISTA/BOVILIS a vaccine lie for respiratory and reproductive infectious diseases in cattle; the NOBILIS be of be and inactivated vaccines protecting poultry against a wide range of viral and bacterial diseases; and CONTINUUM/NOBIVAC a range of canine and feline vaccines. Schering-Plough ordain also have antiparasitics such as SAFE- follow/PANACUR a de-wormer for use in many animal species; anti-infectives such as COBACTAN a broad-spectrum antibiotic for livestock species and horses; and specialty products such as VETSULIN/CANINSULIN a diabetes mellitus treatment for dogs and cats. These products grow on Schering- go's growing presence in this market with products such as NUFLOR a broad-spectrum antibiotic for cattle swine and fish; OTOMAX a canine ear ointment; RESFLOR a combination antibiotic and anti-inflammatory for bovine respiratory disease; as well as the company's animal health services including HOMEAGAIN a U. S proactive pet recovery communicate. The combination also adds five Phase III compounds to Schering-Plough's existing late-stage projects building on a rich and promising pipeline. Schering-Plough's key Phase III projects consider (in alphabetical request): Schering-Plough's world headquarters ordain continue to be in Kenilworth. N. J. As previously reported. Boxmeer the Netherlands ordain become the headquarters of the global animal health business. DISCLOSURE sight: The information in this press channel includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the company's plans its strategies its develop under the Action Agenda its business prospects expected timelines the potential of the Organon BioSciences acquisition and the pipeline of the combined company. Forward-looking statements relate to expectations or forecasts of future events. Schering- go does not assume the obligation to modify any forward-looking statement. Many factors could create actual results to differ materially from Schering- go's forward-looking statements including market forces; economic factors; inaccurate assumptions; the outcome of contingencies such as litigation and investigations; product availability; procure and other intellectual property protection; current and future branded generic or over- the-counter competition; the regulatory process; any developments following regulatory approval; and any scientific developments relating to marketed products or pipeline projects among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements see Schering-Plough's Securities and transfer equip filings including. Part II. Item 1A. "Risk Factors" in Schering-Plough's third quarter 2007 10-Q. Schering-Plough is an innovation-driven science-centered global health compassionate affiliate. Through its own biopharmaceutical research and collaborations with partners. Schering-Plough creates therapies that back up save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "acquire Trust. Every Day" with the doctors patients customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth. N. J. and its Web place is www schering-plough com. communicate: Media. United States. Rosemarie Yancosek. +1-908-298-7476 orInternational. Gail Thornton. +1-908-298-5313 or The Netherlands. MoniqueMols. +31-412-665440 or Investors. Alex Kelly. +1-908-298-7436 all ofSchering-Plough Corporation

Forex Groups - Tips on Trading

Related article:
http://www.biospace.com/news_story.aspx?StoryID=77927&full=1

comments | Add comment | Report as Spam

Online Natural Health Supplements and Products at Low reject Wholesale Prices- Vitamins healthy coffee ganoderma products reishi mushroom. Fish oil. PGFO Ultra Refined look for oil Supplements. Premium pet food. Dog Supplies. Pet Supplies. Puppy Products. General Pet Supplies - beat prices every day on all items - We sell vitamins supplements herbal products minerals omega-3 products at 20% savings” Sign up for a free membership Provides a broad spectrum of antioxidants vitamins minerals natural plant oils and green foods to add a healthy diet. Helps keep good health and well-being. Helps maintain healthy immune and liver answer. Delicious liver flavor to enhance acceptance. Your pet food type should be check every time you buy pet food from your local vendor or ” meaning you will need to be for tainted food ingredients labeled on the packaging of the pet food bag. The challenge you should be asking your self is how do I experience if my pet food is a safe one! here is pet food pet dood recall enumerate that can aid in the what to do if I sight that the pet I buy is a bad one click here for the of poisined tainted pet foods as of 2006 and 2007. Dogs can’t resist the rich aroma of our delicious hickory-smoked pig snouts. Packed with high-quality protein are non-greasy and include no chemical preservatives or flavors. And with no artificial colors you won’t have to worry about hard-to-remove stains in your carpet! They are easily digestible and therefore a safe alternative to rawhide which can create choking throat irritations and potentially dangerous intestinal blockages. Since the digestive system is the first line of immune defense treating your dog to a Porky Puffs won’t put a drive on his or her health desire other highly-processed products on the merchandise today. You’ll feel better providing a interact they’ll like while helping to maintaining a healthy digestive system. And Porky Puffs are appropriate for dogs of all ages. Give your sweet pup something to be truly thankful for – yummy Porky Puffs! are safe and healthy alternative to rawhide treats. Rawhides are cured with harsh chemicals (desire ash-lye solutions and bleach) and are known to cause choking throat irritations and intestinal blockages. Why risk the safety of your precious pup on an inexpensive product when there’s a better option?Our are gourmet grate treats made with 100% natural pork climb and have a lasting mouth-watering flavor your dog ordain like! These yummy treats are naturally high in protein low in fat and are highly digestible. At Healthypetnet we experience ourselves on our caring and knowledgeable customer function staff. You can label us toll free at 877-387-4564 from Monday through Friday 8:00 AM to 7:00 PM Eastern Time when asked for a rep number and label give them this for conformation - NOTE: you cannot join with out this ID# Aaron Rivera Executive Field Rep - My support ID 40006367 for more detailed info online. At HealthyPetNet our pets are move of our families too. We be the best for our pets and we experience you feel the same way about yours. That’s why we declare to give pets with veterinarian formulated products that are inspired by nature and made using good science. Your pet depends on you to make the alter choices when it comes to his or her health and happiness. You can depend on us.

Forex Groups - Tips on Trading

Related article:
http://healthsupply.wordpress.com/2007/10/31/enhancing-the-lives-of-pets-ever-life-animal-health-7-dog-trainersus/

comments | Add comment | Report as Spam

Researchers at the initiate of Animal Health's Compton laboratory have been awarded a commendation described as "Outstanding Contribution by an Academic or Scientific Institution" at the Animal Health Awards for their work in developing a diagnostic evaluate for cattle which undergo been "vaccinated against bovine tb". But is the vaccination of cattle for Tb a viable solution to a problem which is endemic in wildlife?The evaluate as reports is said to differentiate between cattle 'vaccinated against bTb' and those infected with the disease. TB is on the increase in the UK cattle displace costing more than £90m a year and vaccination is under "active consideration" say the Institute of Animal Health. This would involve using the same vaccination used to protect humans against the disease. BCG. However. BCG-vaccinated cattle test positive using the tuberculin climb test. Before a bovine TB vaccination strategy can be implemented a method of distinguishing between vaccinated and infected animals has to be established. With all due respect to the researchers at Compton. Tb vaccine has been "under consideration" for as many years as I can remember. On other forums vaccination of cattle for various disease is under active discussion. Vaccination is used worldwide for some notifiable dieases as an anti- marketing tool and should countries adopt it their produce is automatically disqualified from entry into other trading blocs. The current discussions centre on the midge bourne BTV (bluetongue virus) which had not been reported in the UK before this year. We therefore qualified for "BTV remove status zoning". And for years this country excluded exports of breeding have embryos semen etc from parts of the world whose geographic location encouraged BTV midges and whose stock were vaccinated. Vaccination across Europe is now on the cards but as a compulsory trading bloc which will probably convey in due course that BTV is "de-listed" from its current notifiable status. FMD (Foot and communicate Disease) has similar trading restrictions under OIE and EU trading rules and the inevitable two tier markets develop between countries with endemic disease and vaccination policies and those without either. So why should a cattle Tb vaccine even be considered other than as a reserach project? It's use is strictly limited and its disadvantages many. We asked several epidemiologists and also industry leaders who have connections with export markets and the replies were unequivocal. Unworkable unnecessary and commercial suicide. . I doubt very much that this is the prelude to a vaccination programme for cattle. For a start there is currently no effective vaccine for cattle and I rather doubt there will be. Secondly the idea of vaccinating cattle in the approach of massive contend in the field from infected badgers is daft. Yes vaccination against brucellosis was successful but there was no wildlife reservoir to break down resistance (and the S19 vaccine was a good one) ... So if cattle are the only candidate and there is no wildlife reservoir to break drink resistance to a vaccine it would work. But vaccination minimises an immune response to bacterial contend: it does not stop it altogether. Thus cattle vaccination in the approach of exposure from disease endemic elsewhere would be pointless. And on change as we have said an immediate ban would go from the EU - that's if any pharmaceutical affiliate decided with such a limited market to create a vaccine at all. Only countries with an uncontrolled wildlife reservoir of Tb would be remotely interested. Manufacturers are demanding a 100 million dose guarantee across the EU for BTV-8 vaccine before they'll evaluate of applying for merchandise authorisation so how viable is a Tb vaccine for the West of GB and Wales? Another quote on this subject: If we vaccinated cattle there would be an immediate trade ban with the rest of the EEC. In fact I reckon they are almost waiting for it! Vaccination for badgers is a long term approach which Ireland are currently trialling (or ordain very soon be ). But no vaccine can cope with the current charge of infection in the bedevil population at the moment and strategic culling will be an essential pre requisite. Now that is interesting. We have expressed support for if only to protect them from their infected sett mates but vaccination + disease = death was always the mantra. And it would be that for any vaccination create by mental act to succeed the candidate must be uninfected at the measure of vaccination. So how would the bedevil believe sell the concept of a badger cull as a prerequisite of a badger vaccination programme to its members?But we digress. The evaluate which IAH Compton have developed relies on the information that immune cells of cattle previously infected with TB contain more of the protein gamma interferon than those vaccinated for TB. They exposit the evaluate as able to provide: That sounds suspiciously like PCR. And if it is good. Especially if it is rt-PCR and we're not comfort lagging 6 years behind the plot on this stunning technology. Next step use it to determine bTb in the environment and that is develop. The researchers at Compton comment: "The ultimate acquire of accurate diagnosis of disease in the light of vaccination would be a reduction in the incidence of TB with associated improvements in animal health and welfare and the livelihood of farmers." Don't evaluate so. Vaccination in the approach of an endemically infected wildlife would be ineffective and vaccination would undo the livlihoods of all cattle producers by creating a two tier market - or even no market for their goods. Archaic that may seem but it is the reality of global trading. And what about the cats? And llamas? And free be pigs? ... Anon: 8.53"What would the supply situation if all imports and exports of cattle and cattle products were banned?"Quite simply our population would hurt. We undergo over 60 million populate in the UK and have steadily increased the fit of payments deficit on imported food. We are now very reliant on imports. We merchandise top end value products desire Stilton cease and bottom end aged cattle which for some reason continental Europe appear to favour. The difference in determine on old cow prices with no carcass export. (as now with FMD restrictions) is about £200 / head. So a ban on exports would be a death breathe out to the cattle industry -as we found during BSE. This filters right drink through commodity products desire dried milk crumb and gelatin which finds its way into confectionary on the continent and pharmaceutical coatings. The production processes which use all this type of by product including skins leather etc have been exported desire ago. So the 5th quarter 'bits' now undergo to be exported to connect them. Either that or incinerated at great cost and no value. Current UK government thinking is to let the global retailers give. Their trust in that supply may be misplaced - but that's a whole new blog. And Russian factory ships are hoovering up the herrings - red or otherwise! "Quite simply our population would hurt."Not so. Meat and especially beef (even cattle milk) is not essential in great quantities for a healthy population indeed we'd be healthier eating less meat - I'm not a veggie btw. It is the carbohydrate staples (wheat rice potatoes etc ) that govern whether we starve or not and one can lay out that growing more food crops and fewer livestock (for home consumption as in the past) is more efficient anyway.

Forex Groups - Tips on Trading

Related article:
http://bovinetb.blogspot.com/2007/11/red-herring.html

comments | Add comment | Report as Spam

*/body { background-color: #8c7678; margin:0; font: x-small Verdana. Sans-serif; text-align:center; alter:#333; font-size/* */:/**/small; font-size: /**/small; }/* Page Structure----------------------------------------------- */#outer-wrapper { position:relative; top:4px; left:4px; accent: #888877; width:1000px; margin:10px auto; text-align:left; font: normal normal 110% Verdana. Sans-serif; }#cover2 { lay:relative; top:-4px; left:-4px; accent:#fff; padding:10px; border: 1px solid #fff; }#content-wrapper { width:100%; background-color: #fff;}#main-wrapper { accent: #DFDFBE url("http://www blogblog com/no565/command_main gif") no-repeat alter top; width:710px; float:left; color:#003366; font-size: 85%; word-wrap: break-word; /* fix for desire text breaking sidebar go in IE */ overflow: hidden; /* fix for long non-text content breaking IE sidebar float */ }#main { margin:0; padding:15px 20px; }#sidebar-wrapper { accent:#beb8bc url("http://www blogblog com/no565/sidebar gif") no-repeat left top; width:254px; go:right; padding:0; color: #333333; font-size: 83%; word-wrap: break-word; /* fix for desire text breaking sidebar float in IE */ overflow: hidden; /* fix for desire non-text content breaking IE sidebar float */ }#sidebar { margin:0; padding:2px 20px 10px; }#footer { display:none; }/* Links----------------------------------------------- */a:link { color:#0066CC; text-decoration:none; }a:visited { color: #6728B2; text-decoration:none; }a:hesitate { alter: #6728B2; text-decoration:accent; }a img { border-width:0; }#sidebar a { color: #006699;}#sidebar a:visited { alter: #6131BD;}#sidebar a:hover { color: #6131BD;}/* Header----------------------------------------------- */#header-wrapper { background: #fff; padding-bottom: 4px; }#header titlewrapper { background:#be4 url("http://hamtra googlepages com/DCP_1876. JPG/DCP_1876-full jpg") no-repeat left center; padding:0 0 0 150px; margin:0 0 10px; color:#fff; width:100%; width/* */:/**/auto; width:auto; }#header h1 { accent:url("") no-repeat left top; margin:0; padding:50px 0 50px; line-height: 97px; font: normal bold 303% Helvetica. Arial. Verdana. Sans-serif; text-transform:lowercase; }#header h1 a { alter:#fff; text-decoration:none; } postpage #header h1 { padding-top:0; background-position:0 -40px; } clear { clear: both; }/* Description----------------------------------------------- */#header descriptionwrapper { accent: #6699CC url("http://hamtra googlepages com/flowers jpg/flowers-full jpg"); margin:0 0 6px; padding:0 0 0; color: #ffffff; font-size: 75%; border-bottom: 1px solid #ffffff; }#header description { background:url("") no-repeat left bottom; margin:0; padding:0 0 12px; show:block; line-height: 1.6em; text-transform:uppercase; letter-spacing:.1em; min-height:12px; border-bottom: 1px solid #ffffff;}#header description span { /* To shift the evince next to the description delete the following accent property */ accent:url("") no-repeat left center; /* Keep everything below */ show:block; padding:0 0 0 60px; text-transform:uppercase; letter-spacing:.1em; min-height:12px; } postpage #description em { font-size:1px; line-height:1px; alter:#ffffff; visibility:hidden; }/* Posts----------------------------------------------- */h2 date-header { margin:0 0.5em; line-height: 1.4em; font: normal bold 112% Arial. Verdana. Sans-serif; text-transform:lowercase; alter:#9D1961; } post { margin:0 0 2em; } affix h3 { margin:0 0.25em; line-height: 1.4em; font-weight: bold; font-size: 150%; color:#003366; } post h3 a { text-decoration:none; color:#003366; } post h3 a:link { alter: #003366; } affix h3 a:hover { alter: #6728B2; } post p { margin:0 0.75em; line-height:1.6em; } post-footer { alter:#5D5D46; text-transform:lowercase; } post-footer post-author, post-footer post-timestamp { font-style:italic; } affix blockquote { margin:1em 20px; padding:5px 0; border:2px solid #dec; border-width:2px 0; } post blockquote p { margin:.5em 0; } affix img { adjoin:5px solid #fff; }/* Comments----------------------------------------------- */#comments { margin:2em 0 0; border-top:2px solid #dec; padding-top:1em; }#comments h4 { margin:0 0.25em; font-weight: bold; line-height: 1.4em; font-size: 150%; text-transform:lowercase; color: #366; }#comments-block { margin:0 0 1em 0; line-height:1.6em; } comment-author { margin:0 0.25em; font-weight: bold; line-height: 1.4em; font-size: 112%; text-transform:lowercase; } comment-body. comment-body p { margin:0 0.75em; }p comment-footer { margin:-.25em 0 2em; } deleted-comment { font-style:italic; color:color; } feed-links { alter: both; line-height: 2.5em;}#blog-pager-newer-link { go: left; } #blog-pager-older-link { float: alter; } #blog-pager { text-align: bear on; }/* Sidebar----------------------------------------------- */ sidebar h2 { margin:1em 0.25em; line-height: 1.4em; font: italic bold 26% Arial sans-serif; font-size: 120%; alter: #003366; text-transform:lowercase; } sidebar widget { margin:0.

Forex Groups - Tips on Trading

Related article:
http://discovery-thru-elearning.blogspot.com/2007/09/looking-for-great-volunteering.html

comments | Add comment | Report as Spam

On 23 August the EU Standing Committee on the Food arrange and Animal Health backed the draft decision of the European Commission to limit the restriction on the export of be animals meat and dairy products only to the 10km surveillance zone in Surrey which had otherwise been in force across the UK until now. Hence the ban on British exports to EU countries has been lifted. Therefore the export of be animals meat and dairy products ordain start again within the territory of Great Britain excluding the 10 km zone in the county of Surrey on 25 August – when the decision entered into force. However the change in meat milk and live animal exports will be subjected to stringent controls and veterinary supervision. This decision and the remaining restrictions ordain be reviewed at a meeting of the EU Standing Committee scheduled for 11 September 2007. The merchandise ban has been costing farmers £10m per week. On 3 August the UK authorities confirmed an outbreak of Foot and Mouth Disease (FMD) on a farm in Surrey. The European Commission was informed by the British veterinary authorities that an outbreak of FMD has been officially declared. The Council Directive 2003/85/EC of 29 September 2003 lays down Community measures for the hold back of foot-and-mouth aimed at regaining the disease- and infection-free status of the affected territory. Member States must undergo emergency plans in operation and national compose laboratories must collaborate with the Community Reference Laboratory. All measures foreseen in the above mentioned EU legislation were immediately applied in the UK following the suspicion and subsequent confirmation of the disease including the culling of all animals in the infected premises the establishment of a 3 km (1.8 mile) protection zone and a surveillance zone around the premises of 10km (6.2 miles) where strict movement restrictions are applied as come up as increased biosecurity measures. According to the Directive. Member States shall ensure that the measures applied in the protection govern are kept at least 15 days since the killing and safe disposal of all the animals of susceptible species from the holding and the completion of the preliminary cleansing and disinfection on that holding is carried out. On 6 August the equip adopted a new decision (Decision 2007/552/EC) which laid down interim protection measures reinforcing the measures taken by the UK authorities in reaction to the outbreak of foot-and-mouth disease. The European Commission identified the whole of Great Britain as a high assay area and adopted an emergency measure that all be animals susceptible to FMD (cattle sheep goats and pigs) or products from these animals could not be exported from Great Britain. Then on 8 August at an emergency session the Standing Committee on the Food Chain and Animal Health – consisting of representatives from the Member States and chaired by a European equip representative – voted unanimously in save of a decision to confirm the measures taken by the Commission in lie with EU legislation. Hence the Standing Committee agreed that the whole of Great Britain should remain a high risk zone. On 9 August the European equip adopted a decision concerning certain protection measures against foot-and-mouth disease in the United Kingdom and repealing decision 2007/552/EC which applied until 25 August. This decision provided for measures which are in accordance with the Standing Committee on Food arrange and Animal health’s opinion. No live animals shall be dispatched from or moved through Great Britain. Moreover the United Kingdom shall not dispatch meats coming from or obtained from animals originating in Great Britain. In the same way the UK shall not export meat products of animals coming from Great Britain as well as milk and dairy products. It should be noted that the 2001 foot and communicate epidemic outbreak be the UK economy approximately eight billion pounds. According to Breakingnews. Guy Attenborough. Meat and Livestock Commission’s continue of communications said “the merchandise ban ordain mean a loss of £10m per week to UK red meat businesses.”

Forex Groups - Tips on Trading

Related article:
http://europeanfoundation.blogspot.com/2007/08/eu-lifts-quarantine-on-british-exports.html

comments | Add comment | Report as Spam

Lou Gehrig’s disease also known as amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that gradually erodes go hold back. Death usually follows within three to five years of diagnosis. Currently there is no cure for the condition though a medicate called riluzole helps slow down the progression of the disease and thus prolongs survival by a few months. The researchers say that mice create ALS-like symptoms when they undergo a mutation in a gene called SOD1 which also accounts for one to two per cent of cases among humans. Studies on such animal models have suggested that chemically reactive forms of oxygen that can damage cells also alter to the disease. According to the researchers several proteins present in the bodies of mice and people create reactive oxygen species as part of their normal function in cell signalling and inflammation. Two of such proteins are Nox1 and Nox2 they say. John Engelhardt and his colleagues at the university have found that turning down either of the two genes helps decelerate the progression of ALS symptoms and significantly increases the lifespan of the mice. The researchers say that Nox2 deletion was more effective than the inhibition of Nox1 as it nearly doubled the lifespan of the mice. It also significantly increased the survival list the measure from disease onset to death they add. Neurologist Serge Przedborski of Columbia University in New York has hailed the findings. A chew over published by him last year also showed that eliminating Nox2 prolonged life in ALS mice; but the effect found in that research was much smaller for the mice only survived an additional 13 days. The relatively small increase in lifespan that he had previously observed had discouraged his investigate aggroup from pushing towards human trials. Engelhardt says that differences between the two results could stem from the different genetic backgrounds of the mice used. “The findings give encouraging data that there are new potential therapeutic targets in ALS. Whether our findings will feature out in humans comfort has to be evaluated but our results suggest that inhibiting Nox proteins might significantly compound survival in ALS,” said Engelhardt who also is the Roy J. Carver Chair in Molecular care for. The researchers are now planning to look for drugs that inhibit activation of Nox1 and Nox2. They also will investigate how the SOD-1 mutation leads to hyperactivation of Nox proteins. “The closer we get to clarifying the basic mechanism of how the ALS mutations in SOD-1 bring about to hyperactivation of inflammatory Nox proteins the easier it will be to determine drugs that will interfere with that process,” Engelhardt said.

Forex Groups - Tips on Trading

Related article:
http://www.ebiologynews.com/2967.html

comments | Add comment | Report as Spam

The mistakes that led to on an English do work in August were not the first safety lapse at a British animal health lab this year. A faulty air system in an Institute for Animal Health (IAH) lab handling cattle infected with bovine TB could have exposed up to 14 members of cater - and two inspectors - to the pathogen. The problem surfaced on 1 February at the lab in Compton. Berkshire during a routine inspection by the UK Health and Safety Executive (HSE) which monitors safety at labs working with pathogens capable of infecting humans. It is anyone's guess how long the air system had been faulty and the lab is still closed for investigations. No cater contracted bovine TB. A spokeswoman for the HSE said: "It is highly unlikely that Mycobacterium bovis would have escaped to the wider environment outside Compton. ... The end article is 558 words long. This is a preview of the beat article. If you are a subscriber log in now on the right to act reading. If not and get 4 remove issues plus instant access to all online content. today at only USD $4.95 for your first 4 issues and get New Scientist the world's leading science & technology news magazine delivered direct to your door every week As a magazine subscriber you will benefit from instant access to:

Forex Groups - Tips on Trading

Related article:
http://www.bioethics.net/News/?id=4892

comments | Add comment | Report as Spam